Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK001 allogeneic NK cells with or without subcutaneous IL-2 in AML
NL-OMON55708Phase 1Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RNK001 and aldesleukin in acute myeloid leukemia (AML) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Phase I safety and toxicity, Maximum tolerated IL-2 dose and 1 more. Started Dec 2020; status: recruiting.
02
Drugs
RNK001aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON55708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55708.